Recruiting
Phase 4

Medication

Sponsor:

Sir Mortimer B. Davis - Jewish General Hospital

Code:

NCT07371728

Conditions

Otologic Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Aprepitant

Placebo

Study Details

Brief summary:

This project is being carried out to study the use of a medication to reduce nausea and vomiting after ear surgery.

Conditions

Otologic Disease

Study ID

NCT07371728

Start date

Oct 15, 2026

Status verified date

Jan, 2026

Completion date

Jun 1, 2028

Anticipated

Primary completion date

Jun 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult patients undergoing middle ear surgery including tympanoplasty with or without ossicular chain reconstruction, tympanomastoidectomy or stapedectomy
  • Patient using a hormonal contraceptive will be included, but warned aprepitant may reduce the efficacy of hormonal contraception thus an alternative or backup contraceptive methods should be used for one month after surgery

Exclusion Criteria:

  • Children (<18 years old)
  • Patients unable to complete the post-procedure questionnaire (either due to time constraints, neurocognitive impairment, etc.)
  • Patients taking concomitant medications that are substrates, inhibitors or inducers of CYP3A4 or CYP2CP that are at risk of having a clinically significant effect
  • Patients with a history of hypersensitivity reaction to any of the medications used in the study
  • Patients who are pregnant or breastfeeding
  • Patients unable to receive general anesthesia (i.e. procedures performed under local anesthesia with or without sedation)
  • Patients with severe hepatic insufficiency (Child-Pugh class C)
  • Patients on total intravenous anesthesia (TIVA)

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment Arm

Oral aprepitant 80mg within an hour of induction

placebo comparator: Control Arm

Placebo capsule within an hour of induction

Interventions

Aprepitant

Participants will be randomly assigned to the intervention or control group in a 1:1 ratio. Oral aprepitant of 80mg will be administered within an hour of induction for an otological surgery.

Placebo

Participants will be randomly assigned to the intervention or control group in a 1:1 ratio. An oral placebo capsule will be administered within an hour of induction for an otological surgery.

Primary outcome measure

  • Incidence of clinically important postoperative nausea and vomiting [ Time Frame: 6h to 48h postoperatively ]

Central Contacts and Locations

Central contacts

Locations

Jewish General Hospital

Recruiting

Montreal, Quebec, Canada, H3T 1E2

Contacts

More Information

Sponsor

Sir Mortimer B. Davis - Jewish General Hospital

Last update posted

Nov 19, 2026

Last verified

Jan, 2026

Keywords

  • aprepitant
  • nausea
  • vomiting
  • otologic surgery

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Sir Mortimer B. Davis - Jewish General Hospital on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.